Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
SIRT1, Type H Vessels, and Bone Repair
2026-11-22
Evidence from senescent cell models and aged mice links SIRT1 activation with β-catenin signaling, type H vessel maintenance, osteogenic differentiation, and improved bone architecture. The findings support a vascular–osteogenic mechanism but remain preclinical and pharmacologically bounded.
What RGFP966 Adds to the Celastrol Model
2026-11-21
A critical reading of a lymphoma study shows that RGFP966 functioned as a pharmacological HDAC3 probe, supporting—but not proving—a role for NCOR2–HDAC3 perturbation in celastrol-associated stress and apoptosis.
NCOR2–HDAC3 Signaling in ENKTL Stress
2026-11-20
A mechanistic analysis of how celastrol-associated NCOR2–HDAC3 perturbation, lipid-related stress, and apoptosis were connected in EBV-positive extranodal NK/T-cell lymphoma models, with particular attention to what RGFP966-supported comparisons establish and what remains unresolved.
What RGFP966 Reveals About NCOR2–HDAC3 in ENKTL
2026-11-20
RGFP966 served as a pharmacological HDAC3 comparator in a study of celastrol-induced stress and apoptosis in EBV-positive extranodal NK/T-cell lymphoma models. The findings support NCOR2–HDAC3 disruption as one component of celastrol response, but they do not establish RGFP966 as an antitumor treatment or prove direct celastrol binding to NCOR2.
Why Context Changes the Meaning of a SIRT1 Result
2026-11-19
A study of SIRT1 activation links vascular, osteogenic, and Wnt/β-catenin readouts across senescent cell models and aged mice. Its findings support a context-dependent mechanism for bone repair, but they do not establish clinical efficacy or show that every SIRT1-associated result has the same meaning.
When Laurdan Results Change Meaning
2026-11-19
Laurdan generalized polarization can report membrane hydration and lipid packing, but its scientific meaning depends on the membrane model, comparator, particle state and biological endpoint. A lipid-nanoparticle study of programmable PEG shedding illustrates why a physical-state signal should not be treated as direct evidence of cleavage, uptake, expression or therapeutic benefit.
SIRT1, Type H Vessels, and Bone Repair
2026-11-18
A literature-focused analysis of how Liu et al. connected age-related SIRT1 decline with vascular–osteogenic dysfunction, β-catenin signaling, and impaired skeletal regeneration in cell and mouse models.
SIRT1, Type H Vessels, and Aging Bone
2026-11-18
A literature-focused analysis of how SIRT1 activation was linked to vascular–osteogenic coordination, β-catenin signaling, and improved skeletal regeneration in aged mouse models, with attention to causal limits and translational boundaries.
SIRT1, Type H Vessels, and Bone Repair
2026-11-17
A study in aged skeletal models links SIRT1 activation to coordinated vascular and osteogenic improvement through β-catenin signaling. The evidence is mechanistically coherent within cell and mouse systems, but its clinical and target-specific implications remain limited.
How SIRT1 Couples Bone Vessels to Osteogenesis
2026-11-17
A mouse and cell study links pharmacological SIRT1 activation by SRT1720 to type H vessel abundance, β-catenin signaling, reciprocal paracrine support, and improved bone repair. The evidence is mechanistically suggestive but remains bounded by pharmacological specificity and model translation.
SIRT1, Type H Vessels, and Bone Aging
2026-11-16
A literature-focused analysis of how SIRT1 activation affected vascular–osteogenic coupling in senescent cell models and aged murine bone, with attention to the β-catenin mechanism, internal comparators, and translational limits.
SIRT1, Type H Vessels, and Bone Repair
2026-11-16
A study in Stem Cell Reports links declining SIRT1 activity with age-associated loss of type H vasculature and impaired osteogenesis. Across senescent cell models and aged mice, pharmacological SIRT1 activation improved vascular, osteogenic, and bone-regeneration readouts, with β-catenin signaling emerging as a mechanistic intermediary.
(S)-(+)-Methoprene in Locust JH Signaling
2026-11-15
A mechanistic reading of locust evidence links juvenile hormone analog activity to vitellogenin production and ovarian growth, while separating downstream hormonal effects from upstream miRNA control of juvenile hormone biosynthesis.
SIRT1, Type H Vessels, and Bone Repair
2026-11-14
A study in Stem Cell Reports links reduced SIRT1 activity with age-related loss of type H vessels and impaired osteogenic function. Its findings support a model in which SIRT1 influences endothelial and osteogenic cells through β-catenin-associated Wnt signaling and reciprocal paracrine communication, while leaving important questions about pathway specificity, pharmacological selectivity, and translation to human skeletal disease.
SIRT1, Type H Vessels, and Aging Bone
2026-11-13
A study in senescent cell systems and aged mice linked SIRT1 activation with improved endothelial activity, osteogenic differentiation, type H vessel abundance, and bone microstructure. The findings support a vascular–osteogenic mechanism involving β-catenin and reciprocal paracrine signaling, but they remain preclinical and do not establish clinical efficacy or prove that SRT1720 acts exclusively through SIRT1.